meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/adv melanoma (mML)
mML - (neo)adjuvant (NA)
mML - NA - all population
9
mML - NA - PDL1 positive
1
mML - 1st line (L1)
mML - L1 - all population
7
mML - L1 - BRAF mutant
2
mML - L1 - BRAF wild
3
mML - 2nd line (L2)
mML - L2 - all population
11
mML - L2 - BRAF mutant
1
mesothelioma (MS)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
Immune checkpoint association
nivolumab plus ipilimumab
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-CTLA-4
vs ipilimumab based treatment
vs ipilimumab alone
All patients
Age < 65y (younger)
Age > 65y
ECOG 0
ECOG 1
Gender, female
Gender, male
LDH > ULN
LDH ≤ULN
PD-L1 < 1%
PD-L1 > 1%
stage IIIc
stage IV (metastatic)
stage M0
stage M1A
stage M1B
stage M1C
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
STRAE (any grade)
TRAE (any grade)
TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Arthralgia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Blood creatinine increased TRAE (grade 3-4)
Chorioretinopathy TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Dry skin TRAE (grade 3-4)
Erythema TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Increased lipase level TRAE (grade 3-4)
Maculopapular rash TRAE (grade 3-4)
Myalgia TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Peripheral oedema TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Pyrexia TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Hypothyroidism AE (grade 3-4)
deaths (OS)
mML - L1 - BRAF mutant
metastatic/adv melanoma (mML)
mML - 1st line (L1)
mML - L1 - BRAF mutant
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC
1
certainty unassessable
-14%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open